RESUMO
OBJECTIVE: The objective is to determine the efficacy and safety of paracetamol in preterm babies with hemodynamically significant patent ductus arteriosus (hsPDA). BACKGROUND: In preterm babies, patent ductus arteriosus, when hemodynamically significant, causes considerable morbidity and mortality and also affects 20% of very low birth weight infants. Medical therapy is the mainstay of treatment. Currently used drug cyclooxygenase inhibitor has multiple serious adverse effects, including gastrointestinal perforation, bleeding, and renal failure. Hence, an alternative drug like paracetamol has been proposed for the treatment of hsPDA for fewer side effects. Hence, we used paracetamol in our neonatal intensive care unit in preterm neonates with hsPDA. METHODS: A total of 14 preterm babies diagnosed to have hsPDA on clinical and echocardiographic evaluation in neonatal ICU on days 3-14 of life during 13 months were included. Birth weight was between 1000 g and 1650 g and gestation was between 28 weeks and 33 weeks. Paracetamol in a dose of 15 mg/kg/dose every six hourly given to all the included babies for 3 days and re-evaluated echocardiographically after 3 days of treatment. RESULTS: In 12 (86%) out of 14 cases, PDA was closed, whereas in 2 (14%) hemodynamic closure with insignificant residual flow was achieved. Paracetamol was effective in 100% of cases. No adverse event was observed during treatment. CONCLUSIONS: Paracetamol is a very safe and efficacious drug for treating hemodynamically significant patent ductus arteriosus in premature babies.
Assuntos
Acetaminofen , Permeabilidade do Canal Arterial , Hemodinâmica , Recém-Nascido Prematuro , Humanos , Permeabilidade do Canal Arterial/tratamento farmacológico , Permeabilidade do Canal Arterial/fisiopatologia , Acetaminofen/uso terapêutico , Recém-Nascido , Hemodinâmica/efeitos dos fármacos , Feminino , Masculino , Resultado do Tratamento , Ecocardiografia , Analgésicos não Narcóticos/uso terapêuticoRESUMO
Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can adversely affect extra-pulmonary organs, such as the liver, heart and gastrointestinal tract apart from lungs. Although studies are showing that serum glutamic-oxaloacetic transaminase and serum glutamic-pyruvic transaminase are mildly elevated along with serum bilirubin in adult patients with mild to severe cases of COVID-19 disease, data are limited regarding liver injury in children infected with COVID virus. We report the case of a 9-year-old female patient who developed signs and symptoms of upper respiratory tract infection due to COVID-19 virus infection and subsequently developed fatty liver disease on follow-up. To our knowledge, this is the second case report in children showing an association between non-alcoholic fatty liver disease and SARS-CoV-2 virus infection.
RESUMO
Infant response against infections depends largely on active and passive transfer of immunity through breast milk. There is plenty of data showing transplacental transfer of anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies to the foetus and the presence of neutralising Ig-A and Ig-G anti-SARS-CoV-2 antibodies in the breast milk of mothers post COVID-19 vaccination. There is a paucity of research regarding the impact of COVID-19 vaccination of lactating mothers on the immune response in infant blood. The index case was delivered at 35 weeks of gestation with features of hydrops fetalis. The COVID-19 rapid antigen test and COVID-19 reverse transcription-polymerase chain reaction test were negative for the mother and neonate. The baby was investigated for sepsis, underwent double volume exchange transfusion, and was discharged on exclusive breastfeeding. SARS-CoV-2 antibody titres were tested in blood and breast milk samples 4 weeks after first and second dose of the COVID-19 vaccination of the mother. Growth, neurodevelopment and haematological parameters were monitored over time. A robust immune response was reported in the blood of infants post COVID-19 vaccination of the mother with the potential to confer passive immunity to the baby and without any serious side effects in the mother-infant dyad.
RESUMO
INTRODUCTION: Inappropriate antibiotic (ab)use contributes to antimicrobial resistance. Upper respiratory tract infection (URTI) is the most common reason for antibiotic prescription in an outpatient department (OPD). Several factors influence the high and unjustified antibiotic use in a common ailment. MATERIALS AND METHODS: A clinical audit was performed to assess antibiotic prescription rate (APR) for URTI in the pediatric OPD against the available benchmark. The prescription pattern was assessed, and interventions were formulated to improve prescription behavior. Data of all children attending OPD and fulfilling the criteria for URTI group were collected from the online hospital management system and analyzed. Interventions, in the form of discussions, presentations, posters, and guidelines (Indian Ministry of Health Guidelines for URTI) regarding etiology of URTI, and indications for antibiotic prescription were implemented. Data were monitored and feedback to consultants was given. RESULTS: The baseline APR was 14.7%. There was wide variation in APR (4.1%-53.1%) among consultants. Three consultants had a rate of 53.1%, 29.7%, and 28.6%, which was very high. Postintervention, the average APR decreased to 8.7%, a reduction of 40.8%. There was a reduction in APR among consultants with high APR as well. There was reduction in the use of azithromycin, a drug recommended for patients with penicillin allergy, from 21.2% to 14.4% (32.1% reduction). Amoxycillin plus clavulanic acid combination and amoxicillin alone continued to be the most prescribed antibiotics. CONCLUSION: Interventions through clinical audit were useful in reducing APR. The APR of 8.7% achieved in this study postintervention can be used as a benchmark by other institutions to assess APR in children with URTI.